Knight Therapeutics Inc. (TSX:GUD)
7.65
-0.02 (-0.26%)
Apr 17, 2026, 4:00 PM EST
Knight Therapeutics Employees
Knight Therapeutics had 830 employees as of December 31, 2025. The number of employees increased by 85 or 11.41% compared to the previous year.
Employees
830
Change (1Y)
85
Growth (1Y)
11.41%
Revenue / Employee
542.27K CAD
Profits / Employee
-6.47K CAD
Market Cap
749.97M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 830 | 85 | 11.41% | 830 | 0 |
| Dec 31, 2024 | 745 | 20 | 2.76% | 745 | 0 |
| Dec 31, 2023 | 725 | 27 | 3.87% | 725 | 0 |
| Dec 31, 2022 | 698 | 38 | 5.76% | 698 | 0 |
| Dec 31, 2021 | 660 | -19 | -2.80% | 660 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Trulieve Cannabis | 5,000 |
| Green Thumb Industries | 5,000 |
| Verano Holdings | 3,800 |
| Cresco Labs | 2,900 |
| Organigram Global | 1,137 |
| Aurora Cannabis | 1,073 |
| TerrAscend | 1,038 |
| Canopy Growth | 960 |
Knight Therapeutics News
- 3 days ago - Knight to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference - GlobeNewsWire
- 26 days ago - Knight Amends Normal Course Issuer Bid - GlobeNewsWire
- 4 weeks ago - Investor Outlook: Knight Therapeutics beats estimates on product growth - BNN Bloomberg
- 4 weeks ago - Knight Therapeutics Inc (KHTRF) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic ... - GuruFocus
- 4 weeks ago - Q4 2025 Knight Therapeutics Inc Earnings Call Transcript - GuruFocus
- 4 weeks ago - Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results - GlobeNewsWire
- 4 weeks ago - Knight Therapeutics Wins Approval Of Additional Indication For MINJUVI In Brazil - Nasdaq
- 5 weeks ago - Notice of Knight Therapeutics' Fourth Quarter and Year End 2025 Results Conference Call - GlobeNewsWire